Biotron : 31 Oct 2019Presentation to Investors

	Level 2, 66 Hunter Street
	Sydney NSW 2000
	Tel: [phone]
	Fax: [phone]
	E-mail: [e-mail]
	Website: www.biotron.com.au
31 October 2019
The Manager Companies
ASX Limited
20 Bridge Street
Sydney NSW 2000	(13 pages by email)
Dear Madam
	PRESENTATION TO INVESTORS

I attach a PowerPoint presentation, which is being presented by Biotron Limited's Managing Director, Dr Michelle Miller, at Australia Biotech Invest and Partnering 2019 in Melbourne, Victoria.

Yours sincerely

Peter J. Nightingale

Company Secretary

pjn10133

About Biotron

Biotron Limited is engaged in the research, development, and commercialisation of drugs targeting significant viral diseases with unmet medical need. The Company has BIT225 in clinical development for HIV-1, and a promising preclinical program for HBV. In addition, Biotron has several earlier stage programs designing drugs that target a class of virus protein known as viroporins which have a key role in the virus life cycle of a very broad range of viruses, many of which have caused worldwide health issues such as Dengue, Ebola, Middle East Respiratory virus, Influenza and Zika viruses.

Enquiries
Dr Michelle Miller	Rudi Michelson
Managing Director	Monsoon Communications
Biotron Limited	[phone]
[phone]

BIOTRON LIMITED (ASX:BIT)

Investor Update

October 2019

Forward Looking Statements

This presentation may contain forward-looking statements with respect to the financial condition, results and business achievements/performance of Biotron Limited (ACN 086 399 144) and certain of the plans and objectives of its management. These statements are statements that are not historical facts. Words such as "should", "expects", "anticipates", "estimates", "believes" or similar expressions, as they relate to Biotron Limited, are intended to identify forward-looking statements. By their nature, forward-looking statements involve risk and uncertainty because they reflect Biotron's current expectations and assumptions as to future events and circumstances that may not prove accurate. There is no guarantee that the expected events, trends or results will actually occur. Any changes in such assumptions or expectations could cause actual results to differ materially from current expectations.

Summary

• Unique antiviral drugs targeting big health problems: HIV-1, Hepatitis B, Hepatitis C, Dengue and others
• Phase 2 BIT225 HIV-1 clinical trial induced key immune responses not seen in patients dosed with approved anti- HIV-1 drugs
• World-first:BIT225 targets HIV-1 in long-lived reservoir cells. Could stop chronic life-long infection
• • Phase 2 is the ideal stage for licensing
• Hepatitis B virus (HBV) also area where Biotron drugs show efficacy
• Like HIV-1, HBV current drugs suppress disease. Biotron drugs seeking to eradicate virus - reduce levels of cccDNA, one of the holy grails for new HBV drugs
• Broad portfolio of partnering opportunities across multiple indications

Overview

• Clinical stage drug development company
• • Robust pipeline of drugs targeting serious virus infections
  • Focused on the design and development of a new class of antiviral drugs targeting viral-encoded viroporin proteins
• Lead candidate BIT225 is a novel, first-in-class, oral small molecule drug in development for HIV-1 erdication
• • • Positive data in trials to date including a successful HIV-1 Phase 2 trial
  • Provides clinical validation of Biotron's approach to treating serious virus infections
• Headquartered in Sydney, Australia
• Experienced Board and management team with pharma, financial and VC backgrounds